TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results Investor Conference Call to be Held Today, Tuesday

Therapeutics, Inc. Provides Business Update and Reports Second

Quarter 2018 Financial Results

Investor Conference Call to be Held Today, Tuesday, August 7, 2018

New York, NY, (August 7,

2018) TG Therapeutics,

Inc. (NASDAQ: TGTX) today announced its financial results for the

second quarter ended June 30, 2018 and recent company

Michael S. Weiss, the Company's Executive Chairman and Chief

Executive Officer, stated, "We are extremely pleased with the

progress made in the first half of 2018 and believe we have many

value creating milestones achievable in the near future. This

morning's announcement of complete target enrollment in the

ULTIMATE I & II Phase 3 trials in MS well ahead of our

projections, similar to the rapid enrollment we had seen in our

UNITY-CLL Phase 3 trial, reinforces our belief in the great need

for our product candidates. Mr. Weiss continued, We

believe TG has never been better positioned for success and look

forward to an impactful remainder of the year, and importantly the

announcement of topline overall response rate data from the

UNITY-CLL Phase 3 trial before the end of the

Recent Developments and Highlights

Completed target enrollment into the

ULTIMATE I & II Phase 3 trials in Multiple Sclerosis

Anti-CD47/CD19 License:

Entered into an exclusive global

license agreement with Novimmune SA to collaborate on the

development and commercialization of Novimmune's novel

first-in-class anti-CD47/anti-CD19 bispecific antibody known as

TG-1801 (previously NI-1701).

Ublituximab Data in Multiple

Sclerosis: Presented updated

clinical data from the Phase 2 trial of ublituximab in RMS at the

Congress of European Academy of

Data: Presented the first

preclinical data presentation of TG-1701, the Company's

orally available and covalently-bound BTK inhibitor, at the 23rd

Congress of the European Hematology Association

Umbralisib Data in CLL Patients

Intolerant to Prior BTK/PI3K:

Presented clinical data from the Phase 2 trial of umbralisib in CLL

Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at

Annual Meeting of the American Society

of Clinical Oncology and at the 23rd Congress of the

Ruxolitinib Data in Patients with

Myelofibrosis: Presented

updated clinical data from

its ongoing Phase I study evaluating umbralisib with ruxolitinib,

the JAK 1/2 inhibitor, in ruxolitinib experienced patients with

myelofibrosis at the 23rd Annual EHA Congress.

Data: Presented an integrated

analysis of long term safety data of umbralisib, either dosed as a

single agent and in combination, in patients with relapsed or

refractory lymphoid malignancies at the 23rd Annual EHA

Officer: Announced the hiring

of Adam Waldman, former Celgene executive, as our Chief Commercial

Key Remaining 2018 Milestones

top-line overall response rate results from our UNITY-CLL Phase 3

trial in front line and relapsed or refractory Chronic Lymphocytic

and potentially file the Company's first BLA and/or

enrollment in the current arms of the UNITY-NHL trial, including

the Follicular Lymphoma, Marginal Zone Lymphoma, and Diffuse Large

B-Cell Lymphoma cohorts.

updated clinical data from ongoing oncology trials and final

results from the Phase 2 trial of ublituximab in Multiple Sclerosis

(MS) at major medical meetings during 2018.

Financial Results for the Second Quarter 2018

Cash, cash equivalents, investment

securities, and interest receivable were $126.3 million as of June

Research and development (R&D)

expenses were $38.7 million and $73.7 million for the three and six

months ended June 30, 2018, respectively, compared to $26.7 million

and $49.4 million for the three and six months ended June 30, 2017.

The increase in R&D expense is primarily attributable to an

increase in clinical trial expenses of $10.0 million and $15.7

million, respectively during the three and six months ended June

30, 2018, as compared to prior periods. In addition, included in

R&D expenses for the three and six months ended June 30, 2018

are $1.8 million and $11.4 million, respectively, of manufacturing

and CMC expenses for Phase 3 clinical trials and potential

commercialization. Also included in R&D expense for the six

months ended June 30, 2018 was $4 million ($3 million of which was

recorded in the three months ended June 30, 2018) of non-cash stock

expense recorded in conjunction with the licenses to the BTK and

General and administrative (G&A)

expenses were $5.7 million and $12.3 million for the three and six

months ended June 30, 2018, respectively, as compared to $1.8

million and $6.8 million for the three and six months ended June

30, 2017. The increase in G&A expenses for the three and six

months ended June 30, 2018 relates primarily to non-cash

compensation expenses related to equity incentive expense

recognized during the three and six months ended June 30,

Net Loss: Net loss was $44.1 million and $85.7 million for

the three and six months ended June 30, 2018, respectively,

compared to a net loss of $28.4 million and $56.1 million for the

three and six months ended June 30, 2017, respectively. Excluding

non-cash items, the net loss for the three and six months ended

June 30, 2018 was approximately $36.9 million and $70.1

Net cash utilized for operating

activities during the six months ended 2018 was approximately $62.2

million. The Company believes its cash, cash equivalents,